Showing Records 26-50 of 227 from the Free Pamphlets collection.

= Title is available from your location.

= Title is available once you log in.

= Title is Available - see detailed information page for special access requirements.

= Title is not available from your location.

= Detailed Information Page
G
- Growth Failure In Children With Kidney Disease

- Guidance : Expiration Dating Of Unit-Dose Repackaged Drugs, Compliance Policy Guide

- Guidance : Open Public Meeting : FDA Advisory Committee Meetings

- Guidance For Clinical Investigators, Institutional Review Boards, And Sponsors : Process For Handling Referrals To FDA Under 21 CFR 50.54 : Additional Safeguards For Children In Clinical Investigations

- Guidance for FDA Advisory Committee Members and FDA Staff : Voting Procedures for Advisory Committee Meetings

- Guidance For FDA Reviewers : Premarket Notification Submissions For Transfer Sets (Excluding Sterile Connecting Sets)

- Guidance For FDA Staff And Industry : Marketed Unapproved Drugs, Compliance Policy Guide

- Guidance For Hospitals, Nursing Homes And Other Health Care Facilities

- Guidance For Industry : Postmarketing Studies And Clinical Trials, Implementation Of Section 505(O) Of The Federal Food, Drug, And Cosmetic Act.

- Guidance For Industry : Prescription Drug Marketing Act (PDMA) Requirements, Questions And Answers

- Guidance For Industry : Prescription Drug Marketing Act, Donation Of Prescription Drug Samples To Free Clinics

- Guidance For Industry : SPL Standard For Content Of Labeling Technical Qs & As

- Guidance For Industry : 180-Day Exclusivity When Multiple Andas Are Submitted On The Same Day.

- Guidance For Industry : Court Decisions, ANDA Approvals, And 180-Day Exclusivity Under The Hatch-Waxman Amendments To The Federal Food, Drug, And Cosmetic Act

- Guidance For Industry : Investigating Out-Of-Specification Test Results (OOS) For Pharmaceutical Production.

- Guidance For Industry : Powder Blends And Finished Dosage Units : Stratified In-Process Dosage Unit Sampling And Assessment

- Guidance for Industry : "Lookback" for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV

- Guidance for Industry : 21 CFR Part 11; Electronic Records; Electronic Signatures Validation

- Guidance For Industry : Accelerated Approval Products, Submission Of Promotional Materials

- Guidance For Industry : Acute Bacterial Exacerbations Of Chronic Bronchitis In Patients With Chronic Obstructive Pulmonary Disease : Developing Antimicrobial Drugs For Treatment

- Guidance For Industry : Acute Bacterial Otitis Media, Developing Drugs For Treatment

- Guidance For Industry : Acute Bacterial Sinusitis, Developing Drugs For Treatment

- Guidance For Industry : Acute Or Chronic Bacterial Prostatitis, Developing Antimicrobial Drugs For Treatment

- Guidance For Industry : Addendum To E2C Clinical Safety Data Management : Periodic Safety Update Reports For Marketed Drugs

- Guidance For Industry : Adverse Reactions Section Of Labeling For Human Prescription Drug And Biological Products, Content And Format
